Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ORIGIN: no increased CV and cancer risk with Sanofi's Lantus in early diabetes

This article was originally published in Scrip

Executive Summary

Early use of Sanofi's Lantus (insulin glargine [rDNA] injection) in type 2 diabetes neither raised or lowered the risk of heart attacks, strokes, cancer or cardiovascular-related mortality, researchers found in a large, long-term study, details of which were unveiled at the American Diabetes Associationmeeting in Philadelphia.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC017725

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel